Company intelligence / Profile preview

Guoping Pharmaceutical

Hefei, Anhui, China

Ownership: Private
Development stage: Other

Overview

GFH925 (fulzerasib, Dupert®) approved as China's first and global third selective KRAS G12C inhibitor for NSCLC. Five candidates are in clinical development; ongoing phase II trials for GFH375 and GFH312. Strong R&D reputation; recent patent awarded for peptide extraction technology.

Therapeutic areas: CardiovascularGastroenterologyOncology
Modalities: PeptidesSmall moleculeAntibody-drug conjugateBispecific monoclonal antibody
Industry: Biotech

Partnerships

Collaborations with CROs and two CDMO partners for manufacturing and clinical support (names not disclosed)

Beyond the preview

Go deeper on Guoping Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guoping Pharmaceutical.

Explore the full profile